Fragments of botulinum neurotoxin (BoNT) have been explored as potential targeting moieties and carriers of biomolecules into neurons, although with lower binding and translocation efficiency compared with intact proteins. This study exploits a detoxified recombinant form of full-length BoNT/B (BoTIM/B) fused with core streptavidin (CS-BoTIM/B) for lentiviral targeting to central and autonomic neurons. CS-BoTIM/B underwent an activity-dependent entry into cultured spinal cord neurons. Coupling CS-BoTIM/B to biotinylated lentivirus-encoding green fluorescent protein (GFP) endowed considerable neuron selectivity to the vector as evident from the preferential expression of the reporter in neurons co-cultured with skeletal muscle cells. CS-BoTIM/ B-guided lentiviral transduction with the expression of a SNARE protein, SNAP-25 (S25), rendered non-susceptible to proteolysis by three BoNT serotypes, yielded a sizable decrease in cleaved S25 upon exposure of spinal cord neurons to these toxins. This was accompanied by synaptic transmission being spared from blockade by BoNT/A or BoNT/E, reflecting adequate translation and functional competence of recombinant multi-toxin-resistant S25. The augmented neurotropism conveyed on the lentivirus by CS-BoTIM/B was also demonstrated in vivo through enhanced expression of a reporter in intramural ganglionic neurons in the rat trachea, after injection of the targeted GFP-encoding lentivirus. Thus, a novel and realistic prospect for gene therapy of peripheral neuropathies is offered in this study through lentiviral targeting to neurons by CS-BoTIM/B.
INTRODUCTION
Targeted delivery and expression of ameliorative genes in nerve cells is of high relevance for basic research and front-line medical advancement. 1 Several approaches have been adopted for the selective transfer of vectors into neurons, according to the type of viral vector used. With capsid virions, exogenous ligands or bifunctional antibodies that bind both virus and neuronal ecto-acceptors with high affinities are widely used. 2, 3 In the case of enveloped virions, which include lentiviruses, targeted gene delivery can be achieved by incorporating envelope-attachment glycoproteins. 4, 5 Importantly, although such interventions enhance the viral selectivity for nerve cells, none render transgene expression neuron specific.
Clostridial neurotoxins could provide a superior strategy for targeting vectors to neurons because they recognize and invade cholinergic and certain other neuron types with exceptional specificity. [6] [7] [8] Indeed, the exclusive competency of Clostridial neurotoxins in targeting neurons through high-affinity interaction with their ecto-acceptors offers a promising avenue for guided gene expression in this cell type. Nevertheless, attempts to exploit the exceptional neurotropism of these natural neuron assailants have been limited to the use of heavy-chain or C-terminal acceptor-binding domain (H C ) of Clostridial neurotoxins 9-11 devoid of proteolytically active light chain (LC), which cleaves and inactivates SNAREs, proteins essential for exocytosis. 7 Although such Clostridial neurotoxin fragments are easy to engineer and relatively safe to exploit, their neural uptake after an intramuscular injection proved much inferior to that of full-length prototypes. 12, 13 To circumvent these disadvantages, a full-length atoxic variant of TeNT (tetanus toxin) was developed previously by mutating key residues in the metalloprotease site of its LC, without compromising its capability to invade neurons and exploit intracellular trafficking pathways. 14 In view of its well-known ability to undergo retrograde trafficking with potential trans-synaptic delivery of a payload to inhibitory inter-neurons in the spinal cord, 15, 16 the applications of TeNT seem limited for biomolecule transfer into primary sensory and motor neurons, as well as into autonomic neurons in the periphery. Moreover, widespread immunization against tetanus renders the possible use of full-length inactive TeNT or its heavy-chain fragments as a therapeutic targeting and drug-delivery vehicle to be problematic.
Unlike TeNT, botulinum neurotoxins (BoNTs) are distinguished for their neuroparalytic effects due to peripheral actions at nerve endings, which underlie the severe neurological disorder-botulism. 17, 18 BoNTs exploit endocytosis and the synaptic vesicle recycling machinery for entry into nerves and cytosolic translocation of their proteolytically active LC at the entry site. 6, 19 These characteristics of BoNTs have been explored and successfully exploited for experimental transfer of cargo and enzymatically active proteins into neurons. 20, 21 The suitability of BoNTs as vehicles for neuronal gene targeting and biomolecule delivery is further augmented by the existence of multiple serotypes (A-G), which have different ecto-acceptors for entry into various neuronal populations. 22, 23 The pronounced specificity of BoNT/B for motor nerve endings and peripheral autonomic neurons renders it highly attractive as a potential targeting moiety. Notably, it has the advantages of using as a neuronal acceptor one of the most abundant synaptic vesicle proteins, synaptotagmin II (syt-II), which becomes exposed on nerve terminals upon exocytotic neurotransmitter release. [24] [25] [26] This study introduces a recombinant core streptavidin (CS)-BoTIM/ B-a novel and versatile moiety for neuronal targeting that combines the uncompromised neurotrophism of the full-length yet atoxic protein coupled to CS, a superb adaptor for covalently attaching to a broad range of biotinylated cargo and viral vectors. Its utility for guided gene transfer is highlighted by a greatly improved transduction of reporter green fluorescent protein (GFP) into neurons as compared with other cell types both in vitro and in vivo. The pertinence of the platform established in this study is reaffirmed through expression of a competent multi-toxin-resistant SNAP-25 (MTR-S25) in spinal cord neurons with protection of neurotransmission from a BoNT challenge.
RESULTS

Activity dependence and selectivity of CS-BoTIM/B entry into neurons
The expression in Escherichia coli of the gene construct (pET-29a-CS-BoTIM/B) yielded a putative neuron targeting/delivery vehicle, CS-BoTIM/B-His 6 ( Figure 1a ; Supplementary Figures S1a1 and a2) . Purification by immobilized metal ion affinity chromatography and ion-exchange separation (see the 'Materials and methods' section) gave one major protein band on SDS-PAGE with relative molecular mass B163 k, the expected size for this single-chain protein (Figure 1b) , and displayed the ability to bind biotin-horseradish peroxidase (Supplementary Figure S1b) . Exposure to trypsin converted most of the CS-BoTIM/B to a di-chain containing an interchain disulfide linkage that separated upon electrophoresis under reducing conditions (that is, dithiothreitol) into two bands corresponding in size to that of heavy-chain and CS-LC, the identity of the latter being confirmed by visualization with an anti-streptavidin antibody (Figure 1b) . CS-BoTIM/B (with His 6 attached) fulfills an essential criterion for use as a neuron-targeting moiety because the dichain failed to cause detectable cleavage of a vesicle-associated membrane protein (VAMP2) substrate due to mutation of two residues (E231A and H234Y; Figure 1a ) essential for protease activity, 27 unlike recombinant BoNT/B (Figure 1c ) prepared similarly. Accordingly, the specific neurotoxicity of CS-BoTIM/B in mice (4Â10 5 LD 50 per mg) was greatly diminished being 410 3 -fold lower than that of the wild type.
The ability of CS-BoTIM/B to recognize and selectively invade neurons was assessed by exposing cultured neuronal and muscle cells to this targeting moiety for 1 h with subsequent counting of CS-positive cells, using immunofluorescent staining. Under control conditions, supra-threshold levels of fluorescence (see the 'Materials and methods' section) were observed in o5% of neurons treated with Functionality of MTR-S25 expressed in neurons by CS-BoTIM/B lentivirus reflected by reduced S25 proteolysis and sustained synaptic transmission after treatment with BoNTs The versatility of CS-BoTIM/B in targeting genes to neurons was established through analysis of the proteolytic effects and functional consequences of BoNT/A, BoNT/E or BoNT/C1 in neurons pre-exposed to the targeted vector in which the GFP gene was replaced by that encoding MTR-S25. A triple mutation (D179K, M182T, R198T) of S25 renders it dramatically less susceptible to any of A similar trend was observed with BoNT/C1, although a higher minimal toxin concentration (250 pM) was required to produce detectable cleavage (Figure 5a1 ). In test cultures pre-exposed to CS-BoTIM/B-lentiMTR-S25 before treatment with BoNTs, the minimal toxin dose that produced visible truncation of S25 was shifted considerably towards higher concentrations (125 pM for BoNT/A and BoNT/E and 500 pM for BoNT/C1) ( Figure 5a2 ). As the total amount of S25 in MTR-S25-expressing cultures seems to match that of naive controls when normalized against syntaxin (BoNT/A and BoNT/E) or synaptobrevin/VAMP2 (BoNT/C1) (not shown), the reduced S25 proteolysis in MTR-S25-expressing neurons is attributed to the recombinant S25. It was expected that the presence of BoNT-resistant S25 in cultured neurons would be reflected in the protection of synaptic activity from the inhibitory action of BoNTs. This was assessed by comparing the frequency and amplitude of spontaneous synaptic currents in naive neurons and those treated with CS-BoTIM/B-lentiMTR-S25 exposed to BoNTs (Figures 5b-f ). Under symmetrical Cl À conditions (see the 'Materials and methods' section), both excitatory and inhibitory inputs were detected as inward post-synaptic currents (n¼51). These were almost completely blocked by the broad-spectrum glutamatergic receptor antagonist, kynurenic acid (5 mM), and the GABA A / glycine receptor-coupled Cl À channel blocker, picrotoxin (0.2 mM) (n¼9) (Figure 5b ). In cultures pre-exposed to 200 pM BoNT/A (n¼12) or 600 pM BoNT/E (n¼14), post-synaptic currents were virtually abolished (Figures 5c and d) . In contrast, a significant synaptic activity was seen in BoNT/A-or BoNT/E-treated cultures expressing MTR-S25 (n¼11 and n¼10, respectively) (Figures 5c-f) . Notably, although postsynaptic current amplitudes did not differ between these two groups, their frequency in MTR-S25-expressing neurons exposed to BoNT/E significantly exceeded that of BoNT/A (Figure 5f ). Similar experiments with BoNT/C1 (200 pM) revealed a close to complete inhibition of synaptic transmission in both naive and MTR-S25-expressing cells, indicative of MTR-S25 being unable to protect synaptic transmission from BoNT/C1 challenge (Figures 5e and f) .
In vivo CS-BoTIM/B targets lentiviral GFP expression to ganglionic neurons in the rat trachea To ascertain whether the selective neurotropism of lentivirus endowed by CS-BoTIM/B could be exploited for targeted gene transduction into neurons in vivo, advantage was taken of the readily accessible intramural innervation of the trachea with ganglionic neurons in the tracheal wall amalgamated with several other non-neuronal cell types. 31, 32 Six days after direct injection of lentiGFP or CS-BoTIM/ B-lentiGFP (10 7 viral particles per 5 ml) into the third tracheal ligament, expression of the reporter was detected in both the epithelial and the smooth muscle layers and in neuronal clusters within the inter-cartilaginous space (Figures 6a and b) up to 3.5-4.0 mm from the site of injection (SI) (Figure 6e ) unlike saline-injected controls, which revealed no fluorescence signal (not shown). The cellular agglomerations were confirmed to be local ganglionic neurons following their recognition by an antibody against neuron-specific S25 (Figures 6a1 and b1) . Fluorescence measurements in consecutive coronal sections (25 mm) of the trachea injected with non-targeted or targeted lentiGFP (eight animals per test group) revealed a steep (Figures 6f and g ). These differences became pronounced with increased distance from the SI (0.5-3.5 mm) (Figure 6f ) being statistically significant within the whole range examined (40.5 mm) (Figures 6f and g ). Consistent with the in vitro data described above, these findings are suggestive of a The much more efficient entry of CS-BoTIM/B into neurons compared with non-neuronal cells is noteworthy. In stark contrast to myoblasts which gave negligible uptake of CS even after exposure to high CS-BoTIM/B concentration (2Â10 À4 M), CS was detected in Figure 5 MTR-S25 mitigates S25 cleavage by BoNTs and protects synaptic transmission between cultured spinal cord neurons against blockade by BoNT/A and BoNT/E, but not by BoNT/C1. (a1, a2) Representative western blots of S25 from naive and CS-BoTIM/B-lentiMTR-S25-exposed neuronal cultures, respectively, treated with increasing picomolar concentrations of BoNT/A, BoNT/E or BoNT/C1. The total amount of intact S25 was quantified and compared between the two groups (n¼3 for each) (panels a1 and a2, respectively) with significant differences in intact S25 indicated at concentrations where detected (asterisks). The significantly reduced S25 proteolysis in neurons expressing MTR-S25 must be noted (panel a2). neurons after treatment with nanomolar amounts of this targeting moiety. Such a remarkable difference was further enhanced by stimulation; this significantly increased the level of CS taken into neurons, yet no CS could be found in cultured myoblasts. The considerable decrease in CS-BoTIM/B uptake under low external [Ca 2+ ] and in the presence of BoNT/B or TTX, reflects the pronounced activity dependence of neuronal entry of CS-BoTIM/B, similar to that reported for its parental BoNT/B. 26, 33 The latter offers an additional feature that can be exploited for preferentially transferring biomolecules and gene targeting (see below). It should be emphasized that the confocal analysis herein of the intracellular distribution of CS suggests translocation to the cytosol unlike cargo remaining entrapped within endosomes when attached to BoNT fragments. 11, 20 This discrepancy is perhaps due to the presence of LC in CS-BoTIM/B, capable of H + -dependent translocation and CS release into the neuronal milieu. The recognized high solubility of CS and its low tendency to form high-order aggregates 34 are also consistent with the diffuse presence within cultured spinal cord neurons.
The targeting ability of CS-BoTIM/B was highlighted by the observation of enhanced and preferential lentiviral transduction in spinal cord neurons co-cultured with muscle cells and tracheal ganglionic neurons in vivo. Whereas only a modest gain in selectivity of GFP expression was demonstrated in neurons co-cultured with muscle when using a submaximal titer of CS-BoTIM/B-lentiGFP, its vector-targeting efficiency was striking increased when estimated at a lower viral titer. This together with a more pronounced increase in the fraction of GFP-positive cells reflects an intrinsic lentiviral infectivity for neurons. Similar to the neuronal uptake of CS-BoTIM/B, the transduction and expression of targeted GFP encoding lentivirus manifested activity dependence, as evident from decrease in the fluorescence signal in neurons in the presence of TTX. The highbinding affinity of CS-BoTIM/B to the lumenal domain of syt-II under enhanced vesicle recycling is likely to underpin this effect. As linkage to CS-BoTIM/B did not abolish the viral tropism for muscle cells, the gain in neurotropism could reflect the cooperative binding of targeted lentivirus to the BoNT/B neuronal ecto-acceptor along with vesicular stomatitis virus glycoprotein interaction with phospholipids in the cell membrane. 35 Such a simple mechanism could also explain the enhanced transduction of the CS-BoTIM/B-targeted GFP vector to intramural ganglionic neurons in vivo. Unlike the non-targeted lentivirus, which is more likely to dissipate through systemic clearance from the interstitial tissue of the tracheal wall after injection and yield indiscriminate GFP expression at the SI, the CS-BoTIM/B-linked lentivirus would tend to remain longer in the tissue because of its high-affinity binding to neurons, thereby amplifying production therein of the reporter. In keeping with in vitro experiments using low viral titers, the enhanced GFP expression in neuronal agglomerates remote from the SI in the tracheal wall with the targeted vector is reflective of the increased neurotropism of CS-BoTIM/B-targeted lentivirus. Although our data cannot exclude the retrograde shortrange trafficking of targeted lentivirus, this seems to be unlikely for the following two reasons. First, no retro-axonal transport has been demonstrated conclusively for lentiviral vectors, although this has been seen with other vector systems. [36] [37] [38] Second, the transduction mechanisms of retroviruses and their relatively large size (4100 nm) would strongly disfavour their entrapment within syt-II bearing small synaptic vesicles for retro-axonal trafficking. 39 The viability of CS-BoTIM/B as a moiety for guiding viral vectors to neurons has been established through transduction of functional MTR-S25. Although the expression of toxin-resistant S25 and resultant protection of exocytosis from inhibition caused by several BoNT variants have been reported, 29, 40, 41 these studies used either nonselective or highly invasive tools for delivering vectors with limited gene capacity. Moreover, single point mutations previously introduced into S25 with corresponding protection from only one BoNT serotype at a time undermines their clinical relevance in light of the fact that botulinum can be caused by several BoNTs. 17 The present investigation used a replication-deficient targeted lentivirus with the ability to accommodate much larger gene constructs with bigger inserts (up to 8 kb) 39 and highlights the prospects of transducing viral vectors with multiple functionally relevant mutations. The fact that MTR-S25 protects synaptic activity from BoNT/A or BoNT/E highlights its capability for forming a competent SNARE complex to overcome proteolysis by two serotypes that underpinned a number of human botulism outbreaks. 42 Interestingly, a relatively higher frequency of spontaneous synaptic currents in MTR-S25-expressing neurons exposed to BoNT/E-treated as compared with BoNT/A-treated neurons suggests that MTR-S25 counteracts against BoNT/E inhibition more effectively. The latter, perhaps, reflects the fact that BoNT/Etruncated S25 fails to assemble with synaptobrevin/VAMP and syntaxin into stable SDS-resistant complexes [43] [44] [45] unlike BoNT/A-cleaved S25, which retains limited functionality [45] [46] [47] impeding the replacement of truncated S25 by its toxin-resistant recombinant variant. The cleavage of endogenous SNAREs by perduring active proteases could explain the partial protection of synaptic functions by MTR-S25 from BoNT/A and BoNT/E, whereas the lack of arresting protection of synaptic activity observed with naive and MTR-S25-expressing neuronal cultures exposed to BoNT/C1 accords with its cleavage of additional SNARE protein syntaxins. 48, 49 Notably, these observations are consistent with non-compromised mechanisms that ensure the transfer of palmitoylated S25 to the plasma membrane from Golgi 50 and its adequate membrane association during the post-translational process. This is important given that free cytoplasmic S25 failed to participate in productive exocytosis 51 and because of the necessity for replacing truncated membrane-associated S25 with its toxin-resistant variant. 29 Considering the well-established sensitivity of motor and autonomic nerves to BoNT/B, 52 properties of CS-BoTIM/B described herein render it highly suitable for biomolecule transfer and gene targeting to these neurons. The low efficiency of existing treatments for peripheral neuronal disorders including ganglionopathies and botulism emphasizes the urgent need for vehicles capable of targeted delivery of biotherapeutics to peripheral neurons. An alternative and perhaps more attractive approach could involve the application of advanced gene technologies for functional rescue and treatment of peripheral neuronal disorders by expression of beneficial proteins.
MATERIALS AND METHODS
Engineering of CS-BoTIM/B and lentiMTR-S25, followed by their chemical conjugation pQE60 containing the CS gene (480 bp, 13 k) 53, 54 was restriction digested with BgIII and ligated into pET-29a encoding full-length BoNT/B that had been codon optimized for E. coli, with a C-terminal His 6 tag incorporated. E231A and H234Y mutations were introduced into the BoNT/B metalloprotease site by site-directed mutagenesis. After sequence confirmation, the protein was expressed, and purified by immobilized metal ion affinity chromatography and ion-exchange separation 55 as an SC and subsequently nicked at 22 1C for 1 h using trypsin at a ratio of 1: 200 mg CS-BoTIM/B-His 6 , yielding a di-chain that was used throughout. Western blotting with anti-streptavidin (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:1000 in phosphate-buffered saline (PBS)) detected the presence of the CS-LC in SDS-PAGE gels run under reducing conditions (1 mM dithiothreitol). A synthetic glutathione-S-transferase fusion with VAMP-GFP (GST-VAMP-GFP) acted as the substrate to ascertain whether CS-BoTIM/B contained any protease activity, while determination of its toxicity involved a lethality assay. 55 A replication-deficient lentivirus was produced by transfecting HEK-293FT cells with pWPT-GFP, pMD-2G and pCMV-d-8.74 (Supplementary Figure S4) using polyethylenimine. 56 The protein content of the resultant lentiGFP was measured using bicinchoninic acid and titers determined by p24 enzyme-linked immunosorbent assay (Aalto, Bio Reagents Ltd, Dublin, Ireland). 57 Viral titer is presented as an M.O.I. ratio defined as the number of infectious virus particles deposited in a tissue culture well divided by the number of cells present in the well. Viral infectivity was evaluated with cultured spinal cord neurons exposed to lentiGFP (M.O.I.¼1-10 000) for 48-54 h before counting the GFP fluorescent cells.
Production of lentiMTR-S25 entailed replacing GFP in pWPT-GFP with a His 6 -tagged mutated S25 sequence. In brief, His 6 -S25-R198T already resistant to BoNT/A 29 was rendered additionally non-susceptible to cleavage by BoNT/E or BoNT/C1 by the introduction of two further mutations, namely D179K and M182T, 30 using overlap extension PCR. 41 The lentivirus was biotinylated with EZ-link sulfo-NHS-SS-biotin according to the manufacturer's specifications (Thermo Fischer Scientific, Tintagel, UK) and purified by ultracentrifugation over a 20% sucrose cushion. Biotinylation was quantified using a HABA-avidin kit (Thermo Fisher Scientific) 58 and calculator, as described previously (http:// www.piercenet.com). The biotinylated lentivirus was conjugated to CS-BoTIM/B by passing it through a column of talon resin containing CS-BoTIM/B bound with the His 6 tag. After repeated washing with PBS, CS-BoTIM/B lentivirus was eluted with PBS/1 mM EDTA. The His 6 tag on CS-BoTIM/B lentivirus was subsequently removed by PreScission protease (2 Units per 100 mg CS-BoTIM/B) digestion at 25 1C for 1 h. 59 Viral-mediated expression of MTR-S25 in cultures of spinal cord neurons (see below) was confirmed through total RNA extraction (Qiagen, Crawley, UK), cDNA synthesis (Invitrogen, Carlsbad, CA, USA) and real-time quantitative PCR with probes (FAM-CCAACCAAACTGCAAC-blackhole quencher; TAMRA-GATCGACAG GATCATGGAG-blackhole quencher), using ABI7900 instrumentation and software analysis (Applied Biosystems, Carlsbad, CA, USA).
Culture of spinal cord neurons, exposure to BoNTs and assessment of S25 cleavage
All experimental procedures involving animals had been approved by the Research Ethics Committee at the Dublin City University and the Irish Authorities. Spinal cord neurons were isolated from P1 rats 60 and grown in Dulbecco's modified Eagle's medium (93%), horse serum (5%), N2 supplement (1%), nerve growth factor 2.5S (50 ng ml À1 ), anti-mycotic/antibiotic mixture (1% Gibco, Carlsbad, CA, USA (10 000 Units penicillin, 10 mg streptomycin and 25 mg amphotericin B per ml)); 2Â10 6 cells per dish were plated onto poly-L-lysine (Sigma Aldrich, St Louis, MO, USA)-coated 35 mm culture dishes and grown in 5% CO 2 atmosphere at 37 1C for 3 weeks before experiments. After 24 h and every other day thereafter, the culture supernatant was replaced with a medium containing the anti-mitotic agent cytosine-b-D-arabinofuranoside (Ara-C; 10 mM). Using antibodies against neuron-specific markers (see below), the population of neuronal (84.5 ± 8%, n¼808) versus non-neuronal cells (15.5 ± 7%, n¼150) was estimated in 3-week-old spinal cord cultures. Cocultures were prepared as described above except that C2C12 skeletal myoblasts (passage numbers 2-4) were added to the cultured neurons after 10-12 days, at a density of B1Â10 4 per dish, and Ara-C was removed to allow proliferation of muscle cells for 3 days with Ara-C reapplied before conducting experiments. Neurons in co-cultures were identified using antibodies for neuronal markers (anti-p75 NTR IgG-192 labeled with Cy3 (1:1000) FL-01, Advanced Targeting Systems, San Diego, CA, USA; mouse anti-SNAP-25 (1:500); SMI-81, Synaptic Systems, Goettingen, Germany) (Supplementary Figure S5) .
BoNT/A, BoNT/E or BoNT/C1 (10-1000 pM) were applied to neuron cultures for 1 h by replacing the growth medium with the stimulation buffer (Hank's balanced salt solution supplemented with 60 mM KCl, 2 mM CaCl 2 and 2 mM MgCl 2 ). After washes with Hank's balanced salt solution to remove toxin, normal growth conditions (see above) were returned for 12 h before protein extraction or functional analysis. Proteins were separated by electrophoresis in pre-cast 12% NuPage Bis-Tris gels and the S25 SNARE detected by western blotting (mouse anti-SNAP-25 (1:1000); SMI-81, Synaptic Systems, followed by alkaline phosphatase-conjugated goat anti-mouse secondary antibody (1:1000); A-3688, Sigma) before visualization of bound IgG with a mix of 5-bromo-4-chloro-3¢-indolyl-phosphate p-toluidine and nitro-blue tetrazolium chloride solution (Sigma). Blots were photographed using a Syngene G-box Chemi-16 gel system (Imegen Technologies, Alexandria, VA, USA) and band intensities quantified using Image J (NIH, Bethesda, MD, USA).
Immunofluorescence microscopy of cultured cells
Cell cultures were fixed with paraformadehyde (4%) for 1 h, rinsed (3 times with PBS), permeabilized in PBST (PBS, 0.4% Triton X-100), washed afterwards with PBS (3 times, 10 min), exposed to blocking solution (5% bovine serum albumin, 2% serum in PBS) and incubated in a primary antibody for 1 h at room temperature. Subsequently, fixed cultures were rinsed extensively (PBS), exposed to an appropriate secondary antibody for 1 h at room temperature, finally washed, dried and mounted for microscopic examination. Data acquisition settings and fluorescence intensity threshold (3 times exceeding the background signal intensity) for qualifying fluorescence-positive cells were kept constant throughout the experiments (Supplementary Figure S6) . CS-BoTIM/B uptake and GFP expression were assessed by fluorescence microscopy (Axio Scope, Carl Zeiss, Oberkochen, Germany) equipped with a colored camera (DP-70 CCD, Olympus, Shinjuku, Japan). The efficiency of CS-BoTIM/B uptake (detected by anti-streptavidin, SC-52235, Santa Cruz Biotechnology and goat anti-mouse Alexa 488, Invitrogen) was established in pilot experiments, with 1 h exposure of cultures to 200 nM CS-BoTIM/B and counting of cells using DAPI stain from five randomly acquired fields (n 4500) at a magnification of Â10-20 (Axio Scope, Carl Zeiss). Both GFP and Alexa 488 were detected through the fluorescein isothiocyanate filter (500/ 530 nm band-pass). Subcellular distribution of fluorescence was determined using confocal microscopy (NLO 710, Carl Zeiss). Argon and helium/neon lasers provided the 488 nm (fluorescein isothiocyanate and GFP) and 543 nm (Cy3) lines for excitation, with images sampled in a frame mode at a spatial resolution of 30 nm per pixel and a dwell time of 1.5 ms through a Plan-Apo 40Â/0.95 oil immersion objective.
Neurophysiological recordings of synaptic currents
Recordings were made from cultured neurons in a chamber fixed to the microscope stage (Olympus BX51WI) at 36 1C, under steady perfusion with a standard recording medium. 61 Whole-cell configuration of the patch-clamp technique was used to record spontaneous synaptic currents in the voltageclamp mode, at a holding potential of À80 mV HEKA Digitimeter (HEKA, Welwyn Garden City, UK; EPC-10). Patch pipettes were filled with a cesium chloride-based solution (mM): 150 CsCl, 2 MgCl 2 , 0.01 EGTA, 10 HEPES, 0.4 NaGTP and 4 NaATP, pH¼7.3 (E Cl E0 mV) to achieve adequate voltage clamp and resolution of synaptic currents. The in-bath input resistance of electrodes was B5 MO. The C m was canceled manually and the values of input resistance tabulated for analysis (PatchMaster, HEKA). Inclusion of only healthy neurons in the analysis of currents was assured by the distinctly non-linear voltage-current relationship revealed by slow voltage ramps, stable recordings of synaptic currents at least for 5 min and by discarding cells with C m 435 pF and R inp o150 MÙ . Signals were filtered at 5 kHz, digitized at 10-20 kHz and analyzed off-line (FitMaster, HEKA; Igor Pro, WaveMetrics, Lake Oswego, OR, USA).
Direct tracheal injection of CS-BoTIM/B-lentiGFP in vivo and immunohistochemical assessment of the reporter expression in rat intramural neurons Male Sprague Dawley rats (4 weeks old, 80-100 g, n¼22) were anesthetized (medetomidine (0.4 mg kg À1 ), injected subcutaneously, followed by ketamine hydrochloride (50 mg kg À1 ) intraperitoneally and bupivacaine hydrochloride (5 mg ml À1 ) subcutaneously in the jugular area). A vertical incision was made on the front wall of the neck and the trachea carefully exposed. Bilateral injections of CS-BoTIM/B-lentiGFP (10 7 viral particles in 5 ml, n¼8) into the side walls of the third tracheal ligament were performed. An equivalent dose of non-targeted lentiGFP was similarly injected (n¼8), as well as normal saline (0.9%) for controls (n¼6). After suturing, animals were allowed to recover for 6 days before anesthesia with sodium pentobarbital (200 mg kg À1 , intraperitoneal injection) and fixation by trans-cardial perfusion with PBS/4% paraformadehyde (100 ml). The trachea was dissected out and further fixed in paraformadehyde for 3 h, followed by cryoprotection in sucrose (30% in PBS, pH 7.4) overnight. The tissue was embedded in glue (Tissue Tek, Sakura, Zoeterwoude, The Netherlands) and frozen serial coronal sections (25 mm, starting from the SI) cut and collected in PBS (20 consecutive sections per well (6-well dish), total tissue thickness of sections in each well¼0.5 mm and referred to as a bin size). All sample groups (that is, tracheal sections from normal saline control, LGFP and CS-BoTIM/B-lentiGFP injected animals) were stained for S25 (a neuronal marker; SMI81, Synaptic Systems; 1:1000), followed by goat-anti-mouse Alexa-594 secondary antibody, Invitrogen; 1:1000 in PBS), mounted on super-frost charged-glass microscope slides and coverslipped with a hard-set medium containing DAPI (Vectashield, Vector Laboratories, Burlingame, CA, USA). Image acquisition and criteria for qualifying cells positive for GFP were similar to those specified above.
Statistical analysis
All data are reported as mean ± s.e.m. and statistical significance was assessed using paired or unpaired Student's t-test, with Po0.05 defining a significant difference.
